Scientific Reports (Jan 2022)

Fibroblast growth factor-21 as a novel metabolic factor for regulating thrombotic homeostasis

  • Shuai Li,
  • Haibo Jia,
  • Zhihang Liu,
  • Nan Wang,
  • Xiaochen Guo,
  • Muhua Cao,
  • Fang Fang,
  • Jiarui Yang,
  • Junyan Li,
  • Qi He,
  • Rui Guo,
  • Teng Zhang,
  • Kai Kang,
  • Zongbao Wang,
  • Shijie Liu,
  • Yukai Cao,
  • Xinghao Jiang,
  • Guiping Ren,
  • Kai Wang,
  • Bo Yu,
  • Wei Xiao,
  • Deshan Li

DOI
https://doi.org/10.1038/s41598-021-00906-2
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Fibroblast growth factor-21 (FGF-21) performs a wide range of biological functions in organisms. Here, we report for the first time that FGF-21 suppresses thrombus formation with no notable risk of bleeding. Prophylactic and therapeutic administration of FGF-21 significantly improved the degree of vascular stenosis and reduced the thrombus area, volume and burden. We determined the antithrombotic mechanism of FGF-21, demonstrating that FGF-21 exhibits an anticoagulant effect by inhibiting the expression and activity of factor VII (FVII). FGF-21 exerts an antiplatelet effect by inhibiting platelet activation. FGF-21 enhances fibrinolysis by promoting tissue plasminogen activator (tPA) expression and activation, while inhibiting plasminogen activator inhibitor 1 (PAI-1) expression and activation. We further found that FGF-21 mediated the expression and activation of tPA and PAI-1 by regulating the ERK1/2 and TGF-β/Smad2 pathways, respectively. In addition, we found that FGF-21 inhibits the expression of inflammatory factors in thrombosis by regulating the NF-κB pathway.